A glimpse at OncoSec Medical Incorporated’s potential climb to old highs

As of close of business last night, OncoSec Medical Incorporated’s stock clocked out at $4.85, up 42.23% from its previous closing price of $3.41. In other words, the price has increased by $+1.4400 from its previous closing price. On the day, 2120298 shares were traded. ONCS stock price reached its highest trading level at $5.7001 during the session, while it also had its lowest trading level at $3.4100.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Ratios:

To gain a deeper understanding of ONCS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.30 and its Current Ratio is at 2.30. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on March 08, 2021, initiated with a Buy rating and assigned the stock a target price of $10.

On July 27, 2020, Dawson James started tracking the stock assigning a Buy rating and target price of $10.

H.C. Wainwright Downgraded its Buy to Neutral on November 07, 2018, whereas the target price for the stock was revised from $4 to $1.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 04 when DelAversano Robert J sold 283 shares for $0.37 per share. The transaction valued at 105 led to the insider holds 22,975 shares of the business.

DelAversano Robert J sold 284 shares of ONCS for $202 on Aug 05. The VP, Finance now owns 23,258 shares after completing the transaction at $0.71 per share. On May 06, another insider, DelAversano Robert J, who serves as the VP, Finance of the company, sold 274 shares for $0.83 each. As a result, the insider received 227 and left with 23,542 shares of the company.

Stock Price History:

Over the past 52 weeks, ONCS has reached a high of $39.38, while it has fallen to a 52-week low of $3.35. The 50-Day Moving Average of the stock is 9.3434, while the 200-Day Moving Average is calculated to be 16.4841.

Shares Statistics:

It appears that ONCS traded 3.55K shares on average per day over the past three months and 17.09k shares per day over the past ten days. A total of 1.79M shares are outstanding, with a floating share count of 0.79M. Insiders hold about 0.10% of the company’s shares, while institutions hold 13.90% stake in the company. Shares short for ONCS as of Oct 13, 2022 were 63.23k with a Short Ratio of 0.00M, compared to 81.33k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.16% and a Short% of Float of 0.28%.

Earnings Estimates

As of right now, 1 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.24 for the current quarter, with a high estimate of -$0.24 and a low estimate of -$0.24, while EPS last year was -$0.29. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.19 and low estimates of -$0.19.

Analysts are recommending an EPS of between -$0.9 and -$0.9 for the fiscal current year, implying an average EPS of -$0.9. EPS for the following year is -$0.66, with 1 analysts recommending between -$0.66 and -$0.66.